Delivery Order SPE2DR25D1202-SPE2DR26F71US
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a $2,366.55 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies on October 31, 2025, with completion targeted for November 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies, valued at $1,006.78 under a firm fixed-price arrangement. The award, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, represents a non-competitive delivery order. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,347.67 firm fixed price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector units. The contract, issued on August 22, 2025, with completion targeted for August 25, 2025, represents a non-set-aside, competitively awarded procurement. Performance will be executed from the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector vials valued at $1,789.66. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded a $2,520.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 MG/0.5 ML auto-injector supplies (0.5ML). Issued on September 17, 2025, with completion targeted for September 18, 2025, this delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively issued without set-aside...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for XYOSTED 100MG/0.5ML (a testosterone replacement therapy product) with a ceiling value of $2,407.18. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The award...
- The Defense Logistics Agency awarded a delivery order valued at $1,204.42 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of October 16, 2025. This competitive award, issued on October 15, 2025, utilizes firm fixed pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units valued at $1,094.38 with a firm fixed price structure. This non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F71USDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of XYOSTED 75 mg/0.5 ml auto-injector vials valued at $1,350.39 with completion targeted for October 31, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, to be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026, which serves as the primary pharmaceutical supply vehicle for military and federal healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and other government healthcare systems. The company's DLA Troop Support Medical contract encompasses a comprehensive portfolio of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support military healthcare programs globally. This delivery order for testosterone replacement therapy aligns with the broader pharmaceutical support mission under this prime contract vehicle, demonstrating AmerisourceBergen's continued role as a key supplier of specialized medical commodities to federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 10/30/25 |